Trial Profile
Study of efficacy and remission of ustekinumab (UST) and secukinumab (SEK) in psoriatic arthritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jun 2019
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 28 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting